Wednesday, September 17, 2014 5:14:54 AM
This is from Zack's. AMBS is paying ICON to set up Lympro. If this was a blockbuster test, the lab companies would have been busting down the doors to get to Lympro, AND they would have gotten main stream press coverage.
The coverage that they got from JN was farcical. JN is a paid talking head, willing to spew the company propaganda.
I finally took the time to get the reference, someone told me the other day that ICON paid AMBS, it is the other way around. Oh.
So, Lympro will not be much for a long time, and the Eltoprazine study will not be starting this year. Its starting date will depend on first getting a principal investigator and then getting the Principal to get the study past the IRBs at various institutions. And then there is the issue of grants. The company may have the money to pay for this, but if they cannot get a grant, it speaks to the PD community's urgency to do this study.
The truth is incontrovertible. Malice may attack it, ignorance may deride it, but in the end, there it is.
Winston Churchill
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM